Benjamin J. Hindson - Jan 3, 2022 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact
Stock symbol
TXG
Transactions as of
Jan 3, 2022
Transactions value $
-$3,110,454
Form type
4
Date filed
1/5/2022, 04:15 PM
Previous filing
Dec 30, 2021
Next filing
Feb 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Options Exercise $23.9K +2.08K +1.3% $11.48* 163K Jan 3, 2022 Direct F1
transaction TXG Class A Common Stock Options Exercise $2.95M +39.6K +24.32% $74.58 202K Jan 3, 2022 Direct F1
transaction TXG Class A Common Stock Sale -$332K -2.3K -1.14% $144.56 200K Jan 3, 2022 Direct F1, F2
transaction TXG Class A Common Stock Sale -$2.39M -16.5K -8.23% $145.43 184K Jan 3, 2022 Direct F1, F3
transaction TXG Class A Common Stock Sale -$2.54M -17.4K -9.48% $146.29 166K Jan 3, 2022 Direct F1, F4
transaction TXG Class A Common Stock Sale -$428K -2.91K -1.75% $147.34 163K Jan 3, 2022 Direct F1, F5
transaction TXG Class A Common Stock Sale -$297K -2K -1.22% $148.44 161K Jan 3, 2022 Direct F1, F6
transaction TXG Class A Common Stock Sale -$89.5K -600 -0.37% $149.24 161K Jan 3, 2022 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -2.08K -6.25% $0.00 31.3K Jan 3, 2022 Class A Common Stock 2.08K $11.48 Direct F1, F8
transaction TXG Stock Option (right to buy) Options Exercise $0 -39.6K -29.71% $0.00 93.6K Jan 3, 2022 Class A Common Stock 39.6K $74.58 Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $143.89 to $144.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $144.89 to $145.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $145.89 to $146.8725. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 This transaction was executed in multiple trades at prices ranging from $146.89 to $147.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6 This transaction was executed in multiple trades at prices ranging from $147.93 to $148.925. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7 This transaction was executed in multiple trades at prices ranging from $149.09 to $149.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F8 This option, originally for 100,000 shares, of which 68,750 shares have been exercised, vested as to 1/48th of the shares on May 1, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F9 This option, originally for 136,000 shares, of which 42,370 shares have been exercised, vested as to 1/48th of the shares on May 1, 2020 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

Chief Scientific Officer and President